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The frail older adult subpopulation, which is growing at a
rapid rate, contributes significantly to the increasing glo-
bal healthcare cost [1]. Many frail older adults are immu-
nologically compromised, and, therefore, succumb to
common infections in spite of the availability of antibiot-
ics and other therapeutic measures. It is also not known
how repeated or recurrent infections affect the progres-
sion of the underlying chronic disease. Thus, there is an
urgent need to understand the nature of the diminished
immune capacity of frail older adults, for it could provide
new insight into developing effective intervention modal-
ities. Unfortunately, very little research has been done to
describe and elucidate the immune deficits of the frail
older adults. In the past, researchers have been discour-
aged to study this subpopulation because of its complex-
ity in terms of disease category and disease burden.
In contrast, much is known of the immune status of the
healthy older adult subpopulation, for this subpopula-
tion has been investigated extensively over the past three
decades. Thus, it is known that T cell-dependent immune
functions decline with age [2], and associated with the
decline are structural changes in T cells [3]. However, a
review of more than 200 scientific articles that evaluated
healthy older adults, who were selected on a set of rigor-
ous criteria as defined by the SENEIUR Protocol [4],
showed that the magnitude of decline in T cell-dependent
immune functions with age is modest [5], relative to that
of the aging mouse model [6]. More recently, Sehl and
Yates [7] analyzed changes in various physiologic func-
tions with age from 469 studies involving more than
54,000 healthy and frail older adults. The expansive
review included 43 immunologic studies of 372 individu-
als. They found that the mean annual rate of decline with
age in immune functions is greater than that of other
physiologic functions that were assessed. The authors con-
cluded that the deterioration in immune function in older
adults is due not only to aging, but also the presence of
chronic disease. This review also underscores the need to
evaluate the immune status of frail older adults with
chronic diseases.
Recently, the influence of chronic disease on T cell immu-
nity as been investigated [8], using the Cumulative Illness
Rating Scale (CIRS) [9]. CIRS is an instrument that meas-
ures disease burden in individuals with various chronic
diseases, but with no evidence of acute deterioration or
infection. The CIRS instrument was originally developed
in 1968 and is acknowledged as a user-friendly, compre-
hensive review of medical problems of 14 organ systems
[9]. It is based on a 0 to 4 rating of each organ system. The
scale has been validated in older adults living in long-term
care facilities and congregate apartments in the commu-
nity and has demonstrated better validity in predicting
healthcare outcomes than functional measures [10]. T cell
immunity was based on phytohemagglutinin (PHA)-
induced proliferation and production of immunosup-
pressive interleukin (IL)-10 and immunoenhancing IL-
12. The study showed that decrease in T cell proliferation,
increase in production of IL-10 and decrease in produc-
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tion of IL-12 are linearly correlated with increase in
chronic disease burden (i.e., increased CIRS score), but
not with increase in chronologic age, between 51 to 95
years.
The demonstration that reduced immunity in older adults
is correlated with chronic disease burden, but not with
chronologic age, suggests that chronic disease burden
markedly enhances the reduction in immunity of older
adults caused by biologic aging. Others have suggested
chronic infections, caused by especially cytomegalovirus,
and also by Helicobacter pylori, Mycobacterium tuberculosis,
Chlamydia pneumoniae, Herpes viruses, Epstein-Barr virus,
and Hepatitis viruses, could play a role on progression of
chronic disease, especially atherosclerosis, and impaired
immunity [11-15]. While CIRS does not directly address
prior viral infections, if these infections do impact on pro-
gression of disease it would be predicted that there would
be a correlation between CIRS and evidence of chronic
infection. Chronic infections, increased levels of inflam-
matory mediators, disease progression and frailty have a
very complex association, and, furthermore, an unclear
temporal relationship. Therefore, at this stage of progress,
it would be appropriate and timely, to study the immune
status of frail older adults using an instrument, such as the
CIRS, to categorize frail older adults according to specific
chronic disease and disease burden. The immune status of
frail older adults in each category could then be assessed,
and immunosuppressive factors produced by specific dis-
ease that are present in the microenvironment of immune
cells could be identified and their impact on immunity
mitigated. Consequently, the compromised immune sta-
tus of frail older adults could be boosted to that of healthy
older adults, thereby improving their innate and adaptive
immunologic defense mechanisms to infections and
response to vaccination. This should significantly increase
their resistance to infectious and other immunocompro-
mised-related diseases, possibly slow the progression of
chronic diseases, and, therefore, contribute to the goal of
reducing the global healthcare cost.
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